Kids With Heart NACHD


Herma Heart Institute designation

October 6, 2017

In recognition of the Herma Heart Center’s outstanding clinical care and outcomes, advancements in the field of research and transformational philanthropic support, Children’s Hospital of Wisconsin is proud to introduce its new designation: the Herma Heart Institute — the first such clinical institute for Children's Hospital of Wisconsin.

A history of philanthropic support and partnership leads to world-class care

Children’s Hospital of Wisconsin recently completed an $8 million challenge from John and Susan Herma to benefit the Institute. The $16 million raised from the Herma Heart challenge since April 2017 will support research and clinical innovation, with a focus on eradicating congenital heart conditions and advancing medical care to improve the quality of life for heart patients and their families.

In total, the Herma family has donated more than $25 million over the past 30 years to Children’s Hospital of Wisconsin, helping to transform the cardiac program from a regional service line to an internationally recognized program pioneering advancements in surgical outcomes and clinical care.

The Herma family’s history of contributions include:

  • 1994: Gave $1 million to establish the Leigh Gabrielle Herma Endowed Chair, the first cardiac endowed chair at Children’s Hospital of Wisconsin.
  • 1996: Donated an additional ECMO (Extracorporeal Membrane Oxygenation) to Children’s Hospital of Wisconsin to meet high demand for this life-saving equipment.
  • 2000: Funded the development and staffing of the Wisconsin Pediatric Cardiac Registry, the first systemic collection and analysis of data of children born with congenital heart defects in the state of Wisconsin.
  • 2002: Gave $5 million to establish the Herma Heart Center, now designated the Herma Heart Institute.
  • 2007: Invested $10 million in advancing congenital heart research.

Innovation and inspiration drive Herma Heart Institute

Together we are on a mission to eradicate congenital heart disease

Despite the incredible advancements in survival for congenital heart disease (CHD), more can be done to improve the lives of children and families who are affected. Children’s Hospital of Wisconsin will continue to fundraise for the Herma Heart Institute with a new goal to raise an additional $11 million over the next five years. All gifts will advance research and clinical innovation for kids with congenital heart disease and defects. Individuals interested in supporting the Herma Heart Institute can visit or call the Children’s Hospital of Wisconsin Foundation at (414) 266-6100.

Internationally renowned heart care, right here in the heart of the Midwest

Families worldwide trust the Herma Heart Institute for compassionate, comprehensive and cutting-edge cardiac care for their children. With multiple clinic locations throughout the state of Wisconsin and hospitals located in Milwaukee and the Fox Valley, we provide the most advanced levels of care and follow-up for families, as conveniently as possible.

  • Children’s Hospital of Wisconsin is ranked #5 in U.S. News & World Report Best Hospitals for Pediatric Cardiology and Heart Surgery.
  • Our comprehensive heart care team includes more than 250 highly skilled staff and providers who specialize in pediatric cardiology and lead our many specialty programs.
  • Pediatric heart surgery survival rates at the Institute are among the country's best and have consistently earned us a 3-star rating — the highest possible – by the Society of Thoracic Surgeons.
  • Patient families rate their experience with the Herma Heart Institute 4.9 out of 5 stars.
  • We provide a lifetime of care, from before birth and into adulthood. Our Adult Congenital Heart Disease Program is accredited as a Center of Comprehensive Care by the Adult Congenital Heart Association, the only accredited program in the state and one of only 12 in the country.
  • We provide superior support for out-of-town families with coordination of travel, appointments and gathering of medical records through our Access Center.

Original article can be found on the Children's Hospital Website

New device can monitor mitochondria in the heart to predict cardiac arrest

October 6, 2017

A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital and scientists from Cambridge device maker Pendar Technologies. Their study, conducted in animal models, is the cover article in today's issue of Science Translational Medicine.

"With current technologies, we cannot predict when a patient's heart will stop," says John Kheir, MD of Boston Children's Heart Center, who co-led the study. "We can examine heart function on the echocardiogram and measure blood pressure, but until the last second, the heart can compensate quite well for low oxygen conditions. Once cardiac arrest occurs, its consequences can be life-long, even when patients recover."

The device uses a technology called resonance Raman spectroscopy to measure whether enough oxygen is reaching the mitochondria, the organelles that provide cells with energy. In critically ill patients with compromised circulation or breathing, oxygen delivery is often impaired, making it hard for mitochondria to do their job. This is especially a problem for the heart, which has constant high energy needs.

The current standard for measuring tissue oxygenation, known as mixed venous saturation (SvO2), requires repeated blood draws, adding extra risk in critically ill patients. More importantly, SvO2 cannot tell whether oxygen supply is sufficient to meet the dynamic demands of heart muscle.

"We wanted to create an organ-specific, continuous, reliable readout of how adequately mitochondria are being fed oxygen," says Kheir. "This is the first demonstration of a device that can monitor mitochondria in living tissues to predict impending organ failure."

Using light to monitor mitochondria

This technology is the product of a collaboration between the Translational Research Lab in Boston Children's Heart Center, co-led by Kheir and Brian Polizzotti, PhD, and Pendar Technologies (Cambridge, Mass.). "At the bedside, we saw patients who had a limitation to coronary blood flow, and wanted a device that could provide an early warning sign," Kheir says.

The team created a metric they call 3RMR that uses light readings generated by resonance Raman spectroscopy to quantify oxygenation and mitochondrial function in real time.

When a cell's oxygen levels are too low, its energy balance changes. Electrons start to build up in certain cellular proteins -- hemoglobin, myoglobin and mitochondrial cytochromes. This energy shift reduces or shuts down mitochondrial energy production and can also trigger cell death. All of this sets the stage for organ injury or dysfunction and, in the worst case, cardiac arrest, says Kheir.

Resonance Raman spectroscopy quantifies the fraction of mitochondrial proteins with electrons on them based on how light is scattered when a laser is shined on them. Under low-oxygen conditions, the gain in electrons causes these molecules to distort and, as a result, their spectrum changes.

"This system tells us how satisfied the mitochondria are with their oxygen supply," Kheir explains.

The team used a precise laser and a complex algorithm to distill the information in real time.

"Distinguishing mitochondrial signals from other biological signals with accuracy and speed was the most significant scientific advance here," says Pendar CEO Daryoosh Vakhshoori, PhD, who oversaw the engineering aspect of the project.

Predicting cardiac arrest

Joshua Salvin, MD, MPH and Dorothy Perry, MBChB of the Heart Center, the study's co-first authors, tested the device in rat models. They found that reduced oxygenation of the heart corresponded with elevations in 3RMR, regardless of the cause of reduced oxygen delivery. Elevations of more than 40 percent, measured after 10 minutes of low-oxygen conditions, predicted reduced heart contractility and subsequent cardiac arrest with 97 percent specificity and 100 percent sensitivity, outperforming all other measurement techniques.

The team further tested the device during simulated congenital heart surgery in a pig model. They were able to measure how satisfied the heart muscle was with its oxygen supply, something that cannot currently be done.

"Our likely first application of this device will be to monitor oxygen delivery during and after heart surgery," says Kheir. The current probe is the size of a pen, but eventually, the team would like to develop a smaller probe that could be left inside the chest, so patients could be monitored in the ICU during highest-risk times.

Future applications

Kheir and colleagues also believe the technology could be used to monitor tissue viability in other operations in which tissues and organs are exposed. Potential applications might include monitoring organs intended for transplantation and detection of dangerously reduced blood flow in limbs.

"I think there would be many surgical uses," says Vakhshoori, co-corresponding author on the study. "There really is no technology currently that can assess, in real time, whether oxygen delivery to a tissue is adequate at the level of the mitochondrion."

Kheir also thinks the tool could be helpful in cancer research, since mitochondrial function is central to cancer biology.

The team's goal is to seek FDA approval and commercialize a bedside monitor of mitochondrial oxygenation. In the meantime, Kheir and colleagues plan to seek approval to test the device to monitor heart patients.

Originally posted by News Medical Life Sciences, from Boston Children's Hospital